Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Clin Ultrasound ; 50(7): 953-954, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-35900308

RESUMO

Cavernous hemangioma is a rare, benign tumor and usually uncommon in adults. It is often difficult to diagnose in time because conventional medical imaging examinations usually fail to provide valid information. Clinicians should attach importance to the value of contrast-enhanced ultrasound as an adjunct to rapidly diagnose cavernous hemangioma.


Assuntos
Hemangioma Cavernoso , Adulto , Hemangioma Cavernoso/diagnóstico por imagem , Hemangioma Cavernoso/patologia , Humanos , Tomografia Computadorizada por Raios X , Ultrassonografia
2.
J Bone Miner Metab ; 39(5): 748-756, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-33829324

RESUMO

INTRODUCTION: The incidence of osteoporosis is positively correlated with age. Berberine has been reported to treat osteoporosis due to its beneficial actions on bone formation. However, the direct effects of berberine on senile osteoporosis remain unclear. The present study investigated the protective effects of berberine on senile osteoporosis in mice and preliminarily evaluated its potential mechanism. MATERIALS AND METHODS: 20-month-old male C57BL/6 J mice were used as senile osteoporosis mouse model and treated with strontium ranelate (SR) or berberine or solvent control by daily gavage for 2 months. Thereafter, bone mass and microstructure parameters were assessed. Histological staining was performed to identify the osteogenic, adipogenic and osteoclastic activity of bone tissue. Moreover, role of cAMP/PKA/CREB signaling pathway in berberine affecting bone marrow mesenchymal stem cells (BMSCs) differentiation was clarified by enzyme-linked immunosorbent assay and western blot analysis. RESULTS: The results showed that the SR-treated group displayed a high trabecular bone mass phenotype. For mice administrated with berberine, cancellous bone mass was upregulated in a dose-dependent manner, as indicated by gradually increased bone mass, trabecular bone volume fraction and trabecular number. Furthermore, berberine promotes osteogenic and inhibits adipogenic differentiation of BMSCs via cAMP/PKA/CREB signaling. Also, bone resorption effect becomes more obvious with increasing dose of berberine in vitro. CONCLUSION: The present results suggest that berberine exerts potent bone protective effects by promoting bone formation, inhibiting marrow fat accumulation and bone resorption. This effect may be achieved through cAMP/PKA/CREB signaling pathway.


Assuntos
Berberina , Células-Tronco Mesenquimais , Osteoporose , Animais , Berberina/farmacologia , Diferenciação Celular , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Osteogênese , Osteoporose/tratamento farmacológico
3.
Front Endocrinol (Lausanne) ; 13: 833485, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35273572

RESUMO

Bone diseases are the leading causes of disability and severely compromised quality of life. Neuropeptide Y (NPY) is a multifunctional neuropeptide that participates in various physiological and pathological processes and exists in both the nerve system and bone tissue. In bone tissue, it actively participates in bone metabolism and disease progression through its receptors. Previous studies have focused on the opposite effects of NPY on bone formation and resorption through paracrine modes. In this review, we present a brief overview of the progress made in this research field in recent times in order to provide reference for further understanding the regulatory mechanism of bone physiology and pathological metabolism.


Assuntos
Neuropeptídeo Y , Receptores de Neuropeptídeo Y , Osso e Ossos/metabolismo , Neuropeptídeo Y/metabolismo , Osteogênese , Qualidade de Vida , Receptores de Neuropeptídeo Y/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA